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Research
The incidence of asthma and allergy has
increased dramatically during the past
30 years, primarily in industrialized countries
(Eder et al. 2006). Although improved avail-
ability and quality of medical care account for
some of this increase, the magnitude of the
increase surpasses the rate of improvement in
health care delivery within these countries.
Furthermore, the rate at which this increase
has occurred exceeds the generational time of
these countries, thereby eliminating a strictly
genetic etiology. Consequently, environmen-
tal exposures have become the focus of
research on the rising incidence of asthma and
allergy as well as many other complex diseases.
The National Institute of Environmental
Health Sciences spearheads programs speciﬁ-
cally to define and measure environmental
exposures critical in human disease. The new
Exposure Biology Program within the Genes
and Environment Initiative of the National
Institutes of Health targets gene and environ-
mental exposure interactions resulting in
human disease.
Development of complex diseases or dis-
orders, including asthma, allergy, atherosclero-
sis, diabetes, and obesity, has been linked to
multiple genes or quantitative trait loci within
mammalian genomes (Casas et al. 2006; Shah
et al. 2006). Multigene interactions are now
suspected in most complex diseases (Chan
et al. 2006; Motsinger et al. 2007; Yang et al.
2005). Increasingly, gene–environment inter-
actions are also being examined for a role in
the etiology of complex diseases (Colilla et al.
2003; Criswell et al. 2006; van Dellen et al.
2005; Williams et al. 2006). Through general-
ized fetal stress or specific biochemical reac-
tions, in utero environmental exposures appear
to mediate complex chronic diseases (cardio-
vascular disease, obesity, diabetes, asthma) hav-
ing recognized genetic components (Genuis
2006; Martinez 2007; Okubo and Hogan
2004). Recent ﬁndings implicate in utero envi-
ronmental exposures in developmental disor-
ders such as autism (Ashwood et al. 2006).
Although mild-to-moderate environmental
exposures may not alter basic genetic informa-
tion (DNA sequence), these exposures can
determine the expression or repression of
essential genes at developmentally critical
points (Dolinoy et al. 2007; Li et al. 2003),
thus contributing to chronic disease.
Altered lung function, increased asthma
risk, and persistent lung function deficits in
children (Gilliland et al. 2000, 2001; Li et al.
2000) have been associated with maternal
smoking during pregnancy (in utero expo-
sure). Environmental tobacco smoke (ETS)
aggravates childhood asthmatic responses
(Gilliland et al. 2000; Lindfors et al. 1999;
Mannino et al. 2001), and premature adult
cardiovascular disease in mice (Yang et al.
2004) is promoted by in utero ETS exposure.
Altered lung function, exacerbation of
symptoms, and acceleration of the disease
processes seen with smoke exposure might
arise from direct injury suffered by a develop-
ing fetus, by alteration of fetal gene expres-
sion, or through a combination of fetal injury
and protective alteration of gene expression.
Fetal sensitivity to ETS may be heightened, or
ETS components may bioaccumulate as
demonstrated by higher cotinine levels in
neonates compared with their nonsmoking
mothers who had received ETS exposure dur-
ing pregnancy (Perera et al. 2004).
Ovalbumin (OVA) is an allergen com-
monly used in rodent models of allergic
asthma. OVA sensitization by ip injection fol-
lowed by inhalation challenge with OVA
aerosol elicits expansion of the T-helper 2
(Th2) lymphocyte population. Production of
Th2 cytokines follows, leading to airway
hyperresponsiveness (AHR) and inﬂammation
characterized by eosinophilia and appearance
of OVA-specific immunoglobulin (Ig) E
(Zhang et al. 1997). This sensitization and
challenge protocol does not mimic the typical
human experience of aerosol-only sensitization
and challenge (Bice et al. 2000). However,
aerosol-only OVA exposure of mice results in
little or no OVA-speciﬁc serum IgE, and no
eosinophilic inﬂammatory response.
Within this context, we designed experi-
ments (Figure 1) to simulate the respiratory
consequences to offspring of daily gestational
exposures to ETS or filtered air (Penn et al.
2007). We combined daily in utero ETS
exposure with postnatal OVA inhalation to
test the hypothesis that in utero ETS exposure
alters airway function and immune responses
in adults. At 10 weeks of age, in utero ETS
and in utero air mice received aerosol OVA
exposures. The in utero ETS mice displayed
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BACKGROUND: In utero environmental tobacco smoke (ETS) exposure exacerbates initial
lung responses of adult mice to ovalbumin (OVA), a common allergen in rodent models of
allergic asthma.
OBJECTIVE: We tested the hypothesis that in utero ETS exposure alters expression of genes (includ-
ing asthma-related and inﬂammatory genes) in the lungs of adult mice and that this differential
expression is reﬂected in differential respiratory and immune responses to nontobacco allergens.
METHODS: Using Affymetrix Mouse Genome 430 2.0 arrays, we examined gene expression changes
in lungs of BALB/c mice exposed to ETS in utero, OVA, or saline aerosol at weeks 7–8, and OVA
sensitization and challenge at weeks 11–15. Data sets were ﬁltered by transcript p-value (≤ 0.05),
false discovery rate (≤ 0.05), and fold change (≥ 1.5). Differential expression of selected genes was
conﬁrmed by polymerase chain reaction (PCR).
RESULTS: Genes differentially expressed as a result of in utero ETS exposure are involved in regula-
tion of biological processes (immune response, cell proliferation, apoptosis, cell metabolism)
through altered cytoskeleton, adhesion, transcription, and enzyme molecules. A number of genes
prominent in lung inﬂammation were differentially expressed on PCR but did not pass selection
criteria for microarray, including arginase (Arg1), chitinases (Chia, Chi3l3, Chi3l4), eotaxins
(Ccl11, Ccl24), small proline-rich protein 2a (Sprr2a), and cytokines (Il4, Il6, Il10, Il13, Tnfa) .
CONCLUSION: The differential lung gene expression reported here is consistent with previously
reported functional changes in lungs of mice exposed in utero to ETS and as adults to the non-
tobacco allergen OVA.
KEY WORDS: allergy, asthma, environmental tobacco smoke (ETS), gene regulation, in utero, inﬂam-
mation, lung, ovalbumin. Environ Health Perspect 115:1757–1766 (2007). doi:10.1289/ehp.10358
available via http://dx.doi.org/ [Online 19 September 2007]significantly increased AHR without signifi-
cant changes in histopathology, cytokine pro-
files, or antibody levels. At 15 weeks of age
after OVA sensitization and challenge,
in utero ETS mice not previously exposed to
OVA exhibited significantly increased AHR
compared with in utero air controls. ETS
mice previously exposed to OVA demon-
strated decreased numbers of bronchoalveolar
lavage (BAL) eosinophils and polymorphonu-
clear leukocytes (PMNs), diminished AHR,
and lower levels of interleukin (IL)-4, tumor
necrosis factor (TNF)-α, and interferon
(IFN)-γ compared with that of air controls.
In the present study we examined differen-
tial gene expression proﬁles in lungs of adult
mice from four treatment groups [ETS-,
saline-, and OVA-exposed (ESO); HEPA-
ﬁltered air-, S-, and O-exposed (ASO); E- and
O-exposed, then O-exposed (EOO); A- and
O-exposed, then O-exposed (AOO); Figure 1]
using extracted mRNA. We extracted RNA
from lung tissue taken concommitantly with
histopathology, clinical pathology, and
immunology samples (Penn et al. 2007). No
sex differences were detected in immune
responses, lung function, or histopathology of
offspring in that study. Nevertheless, RNA for
individual microarray analyses in this study
was examined from females only (four females
per treatment group) to eliminate any unrec-
ognized sex effects. We used polymerase chain
reaction (PCR) to further examine selected
asthma-related and inflammatory genes in
these subsets of each treatment group and to
determine whether the differential gene
expression levels were consistent with the
pathophysiology and the immune system
responses that we previously reported (Penn
et al. 2007).
Materials and Methods
Animal protocols. We housed and handled
8-week-old BALB/c mice (Harlan, Indianapolis,
IN) according to the Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory
Animal Resources 1996). The Louisiana State
University Institutional Animal Care and Use
Committee approved all animal procedures.
We handled all animals humanely and took
care to ensure alleviation of pain and suffering.
Exposures. Pre- and postnatal exposure
protocols have been described in detail (Penn
et al. 2007). Briefly, we exposed pregnant
mice in dynamic exposure chambers to either
ETS mixed with HEPA-ﬁltered air [ﬁnal total
suspended particle (TSP) concentration =
10 mg/m3; carbon monoxide concentration
44.5 ppm] or to HEPA-ﬁltered air 5 hr/ day
for days 1–19 of gestation. Half of each of
these groups inhaled 1% OVA aerosol
(20 min/day for 10 days at 7–8 weeks of age)
to produce tolerance, while the other half
inhaled saline aerosol. We OVA-sensitized,
challenged (Figure 1), and then sacriﬁced all
mice 1 day after ﬁnal challenge at 15 weeks of
age to determine the effects of in utero ETS
exposure on responses to OVA sensitization/
challenge in mice not previously exposed to
OVA (ESO, ASO) and on OVA tolerance in
mice previously exposed to OVA (EOO,
AOO). There were no postnatal offspring
exposures to ETS after birth.
Lung harvest and mRNA extraction. We
excised left lung lobes [AOO (n = 21), EOO
(n = 18), ASO (n = 20), ESO (n = 17)], placed
them in RNAlater, and stored them at –80°C.
Subsequently, we transferred these samples to
1 mL TRIzol (Invitrogen, Carlsbad, CA) and
homogenized them using a Mixer Mill MM
300 (QIAGEN, Valencia, CA) with a copper
bead. We added chloroform to the homogen-
ate, mixed by inversion, and centrifuged at
4°C to separate phases. We transferred the
RNA-containing aqueous phase to an RNeasy
Micro Kit (QIAGEN). We followed the man-
ufacturer’s protocol, omitting buffer RLT. We
eliminated remaining DNA using a column
RNase-Free DNase set (QIAGEN). We used
an additional buffer RPE wash to remove
residual salts, followed by an additional 2-min
spin to evaporate residual ethanol.
We checked RNA samples quantity and
purity with a NanoDrop ND-1000 Spectro-
photometer (NanoDrop, Wilmington, DE).
Values generated from the NanoDrop for all
samples fell into the following ranges: 260/280
ratio: 2.09–2.17; 260/230 ratio: 2.20–2.27;
concentration: 1,200–1,900 ng/µL. We per-
formed further quality assays on 1:5 dilutions
of RNA samples with an Agilent 2100
BioAnalyzer and Agilent RNA 6000 Nano
Series II Kits (Agilent Technologies, Palo Alto,
CA). All samples fell into the following
ranges: 28S/18S ratio: 1.3–1.8, RNA integrity
number: 8.5–9.6.
Microarray assay. We assessed global gene
expression in the lung in individual mice
(four female mice per treatment group) on
Affymetrix Mouse Genome 430 2.0 Arrays
representing more than 39,000 transcripts
with over 45,000 probe sets. The arrays were
processed at the Research Core Facility of
Louisiana State University Health Science
Center-Shreveport.
Double-stranded cDNA synthesized from
total RNA was used to create cRNA, which
was then biotinylated, fragmented, and added
to a hybridization cocktail that included probe
array controls, bovine serum albumin, and
herring sperm DNA. This cocktail was then
hybridized (16 hr at 45°C) to oligonucleotide
probes on a GeneChip Mouse 430 2.0 Array
in a GeneChip Hybridization Oven 640.
Immediately after hybridization, the array
underwent an automated washing and stain-
ing protocol on a GeneChip Fluidics Station
and was scanned with a GeneChip Scanner
3000. Data collection and processing of initial
raw data were performed by a GeneChip
Workstation. All gene chips and instrumenta-
tion were from Affymetrix (Santa Clara, CA).
Gene expression analysis. We sent
GeneChip Workstation data to Expression
Analysis Systems (Durham, NC). Initially, a
principal component analysis was used to
determine clustering of experimental units.
The analysis revealed clustering by treatment
group with greater variation between groups
than within groups (data not presented), thus
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Figure 1. Exposures and timeline. Three 20-min inhalation exposures to 1% OVA in saline, every other day
at 14 weeks plus an additional 20-min exposure 1 day before sacriﬁce at 15 weeks constituted OVA chal-
lenge; Abbreviations: AIR = HEPA-ﬁltered air; ESO = ETS-, saline-, and OVA-exposed; ASO = HEPA-ﬁltered
air-, S-, and O-exposed; EOO = E- and O-exposed, then O-exposed; AOO = A- and O-exposed, then O-exposed. 
aDays 1–19 of gestation. bWeeks = age of offspring. cTreatment group designation based on gestational,
8-week, and 11- to 14-week exposures. dTolerize = OVA tolerization established through inhalation of 1%
OVA aerosol (in saline), 20 min daily for 10 days. eSens/chal = OVA sensitization was established by ip








OVA tolerized OVA sens/chale
OVA tolerized OVA sens/chale
OVA sens/chale Saline aerosol
OVA sens/chale Saline aerosol
Exposures: Gestationala
(in utero)
7–8 weeksb 11–14 weeksb Designationcvalidating subsequent comparisons between
treatment groups. Before making these com-
parisons, data were subjected to reduction of
invariant probes (REDI) to remove previously
determined mal-performing probes from the
data set. Pairs of treatment group data under-
went permutation analysis for differential
expression (PADE) that accounts for false
positives by tabulating a false discovery rate
(FDR) based on a permutation-generated
reference curve (technical information on
REDI and PADE analyses available at
www.expressionanalysis.com). After REDI
and PADE, expression data were tabulated for
each remaining transcript, including individual
In utero ETS alters adult lung gene expression
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Table 1. Genes differentially expressed by microarray in OVA-sensitized mice exposed in utero to ETS or AIR (ESO vs. ASO).a
Fold Transcript Gene
Affymetrix ID change FDR p-value symbol Protein family Function Process
1448303_at 3.25 0.040 0.0018 Gpnmb Enzyme Integrin binding Inhibit proliferation
1441557_at 2.12 0.040 0.0008 Setd8 Methyltransferase Histone (H4) methylation Control cytokinesis
1424706_at 2.02 0.037 0.0003 Zfp51 Zinc ﬁnger protein DNA/protein binding Unknown
1444396_at 2.01 0.040 0.0008 Trp53inp2 Unknown Unknown Unknown
1424704_at 1.98 0.037 0.0002 Runx2 Transcription regulator Transcription inhibitor Inhibit proliferation
1421525_a_at 1.92 0.037 0.0002 Birc1e Receptor (PRR) Unknown Macrophage activation/death
1450541_at 1.89 0.037 0.0003 Pvt1 Unknown Unknown Unknown
1453281_at 1.88 0.040 0.0006 Pik3cd Kinase VEGF activation Promote immune responses
1434500_at 1.67 0.037 < 0.0001 Ttyh2 Ion channel protein Chloride channel Chloride channel regulation
1456868_at –3.37 < 0.001 0.0004 Mrcl3 Myosin light chain Cytoskeleton actin binding Motility, elasticity, apoptosis
1457610_at –2.91 < 0.001 0.0006 Rbck1 Transcription regulator Zinc and protein binding Ubiquitinization
1433774_x_at –2.81 < 0.001 0.0006 Cog1 Tranport protein Protein binding Golgi transport
1441840_x_at –2.78 < 0.001 0.0001 Kiaa0963 Unknown Unknown Unknown
1447530_at –2.77 < 0.001 0.0012 F8a F actin binder Endosomal binding/motility Endosomal formation/function
1440180_x_at –2.76 < 0.001 < 0.0001 Zbtb3 Zinc ﬁnger domain DNA/protein binding Unknown
1458354_x_at –2.62 < 0.001 0.0006 Krt28 Keratin Unknown Unknown
1443829_x_at –2.55 < 0.001 0.0001 Coasy Kinase Adenylyltransferase Coenzyme A regulation
1455853_x_at –2.43 < 0.001 0.0009 Tspan31 Tetraspanin Transmembrane protein Proliferation, differentiation, growth
1449804_at –2.36 0.040 0.0036 Pnmt Methyltransferase Tyrosine metabolism Growth
1458325_x_at –2.34 0.040 0.0043 Bmf Protein binding Cytoskeleton myocin binding Cell repair/induce apoptosis
1436149_at –2.23 0.037 0.0020 Cox5b Enzyme Cytochrome c subunit Oxidative phosphorylation
1427527_a_at –2.20 < 0.001 0.0001 Pthlh Hormone Calcium binding Proliferation, differentiation, growth
1443752_at –2.17 < 0.001 0.0009 Kiaa1529 Unknown Unknown Unknown
1438638_x_at –2.17 0.037 0.0020 Fam116b Unknown Unknown Unknown
1459766_x_at –2.14 < 0.001 0.0004 Sf1 Transcription regulator Activate transcription Proliferation, differentiation, growth
1421788_x_at –2.13 < 0.001 0.0011 Klk13 Peptidase Unknown Unknown
1421621_at –2.10 < 0.001 0.0003 Rasgrf2 Guanyl exchange factor Guanyl nucleotide exchange Growth and signaling
1452538_at –2.08 < 0.001 0.0006 Igh-V3609Nb Ig super-family Antigen binding Proliferation, differentiation, growth
1456746_a_at –2.08 < 0.001 0.0005 Cd99l2 Membrane protein Unknown Unknown
1441935_at –2.07 < 0.001 0.0002 Ankra2 Transcription regulator Activate transcription Proliferation, differentiation, growth
1419216_at –2.04 0.040 0.0032 Azi1 Centrosomal protein Unknown Unknown
1426325_at –2.02 0.037 0.0015 Kif1c Kinesin Cytoskeleton binding protein Motility and Golgi transport
1424845_a_at –1.94 0.037 0.0011 Cep68 Centrosomal protein Unknown Unknown
1449218_at –1.91 0.037 0.0019 Cox8b Enzyme Cytochrome assembly Oxidative phosphorylation
1425155_x_at –1.88 0.037 0.0017 Csf1 Transcription regulator Activate transcription Proliferation, differentiation, growth
1433792_at –1.87 0.040 0.0026 Nrip2 Transcription regulator Inhibit transcription Unknown
1439745_at –1.84 0.037 0.0010 Cacng7 Ion channel protein Calcium channel Calcium channel regulation
1425120_x_at –1.83 0.040 0.0019 Fam14a Unknown Unknown Unknown
1454634_at –1.83 0.037 0.0014 Fuk Kinase Glycoprotein phosphorylation Leukocyte trafﬁcking
1419387_s_at –1.83 < 0.001 0.0005 Muc13 Mucin Transmembrane protein Unknown
1440368_at –1.83 0.040 0.0023 Jmjd2b DNA binding Unknown Unknown
1459977_x_at –1.81 0.037 0.0011 Cox10 Enzyme Heme synthesis Oxidative phosphorylation
1450704_at –1.81 0.037 0.0010 Ihh Enzyme Transferase Proliferation, differentiation, growth
1416518_at –1.77 0.040 0.0019 H1foo H1 histone protein DNA and chromatin binding Chromatin folding
1417305_at –1.77 0.040 0.0019 Des Desmin Cytoskeleton binding protein  Smooth muscle motility/elasticity
1435015_at –1.75 < 0.001 0.0005 Zfp787 Zinc ﬁnger protein DNA/protein binding Unknown
1426274_at –1.74 < 0.001 0.0001 Slc9a8 Solute carrier protein Sodium/hydrogen exchange Unknown
1439144_at –1.74 < 0.001 0.0001 Cwf19l1 Protein binding Unknown Cell cycle control
1430236_s_at –1.74 < 0.001 0.0001 Gdsm2 Unknown Unknown Unknown
1450538_s_at –1.72 < 0.001 0.0003 Mcpt9 Peptidase Peptide catabolism Mast cell degranulation
1448927_at –1.70 0.040 0.0012 Kcnn2 Ion channel protein Potassium channel Potassium channel regulation
1427409_at –1.68 0.037 0.0010 9-Mar Ring ﬁnger protein Unknown Unknown
1436083_at –1.67 0.037 0.0009 Lrp3 Receptor (TM) Lipoprotein binding Adhesion, apoptosis
1434463_at –1.65 0.037 0.0009 Bfsp2 Phakinin Cytoskeleton component Motility, elasticity, structure
1459073_x_at –1.63 0.040 0.0011 Fgf14 Growth factor Ion channel protein binding Sodium channel regulation
1421975_a_at –1.63 0.040 0.0015 Add2 Adducin Cytoskeleton actin binding Motility, elasticity, structure
1421329_a_at –1.61 0.037 0.0004 Smyd1 Transcription regulator Inhibit transcription Chromatin remodeling
1426493_a_at –1.61 < 0.001 0.0001 Kifc2 Kinesin Cytoskeleton binding protein Motility and Golgi transport
1432883_at –1.59 0.037 0.0006 Wdr87 Unknown Unknown Unknown
1420569_at –1.58 < 0.001 < 0.0001 Chad  Chondroadherin Unknown Chrondrocyte adhesion
AIR, HEPA-ﬁltered air. Gene annotations are from Affymetrix GeneChip Mouse Genome 430 2.0 Array (http://www.affymetrix.com/products/arrays/speciﬁc/mouse430_2.affx).
aMice were exposed in utero to ETS or AIR (HEPA-ﬁltered air), and then OVA-sensitized by ip injections and challenged with aerosol OVA as described in “Material and Methods.”
bHuman homologue IGH-1A.transcript p-value, FDR, fold change,
Affymetrix probe ID, gene symbol, and func-
tional summary. All transcripts included in
this study had a fold change of at least 1.5 (up
or down), and both an individual p-value and
FDR < 0.05.
Pathway analyses. We analyzed gene
expression data with the network- and path-
way-building software Ingenuity Pathways
Analysis 4.0; gene networks and canonical
pathways were examined using the Ingenuity
Analysis Knowledge Database (Ingenuity
Systems, Redwood City, CA). We identiﬁed
and scrutinized networks and pathways for
phenotypic relevance. We identified select
genes from the literature for conﬁrmation by
quantitative real-time PCR (qRT-PCR)
analysis. We created custom networks to
demonstrate the connections between the
genes identiﬁed in our expression analyses.
qRT-PCR. Cytokine changes that were
apparent at the protein level [IL-4, IL-5,
IL-10, IL-13, TNF-α (Penn et al. 2007)]
were not seen in the ﬁltered microarray data.
In addition, several asthma-related genes did
not pass all the filtering criteria and conse-
quently were not identiﬁed in the ﬁltered data
as being differentially expressed, although pre-
liminary data suggested otherwise. To clarify
the status of these genes, the same RNA sam-
ples that had been subjected to the microarray
assay underwent qRT-PCR to determine dif-
ferential expression of 14 genes previously
associated with asthma by other investigators
(Arg1, Ccl8, Ccl11, Ccl24, Ear11, Mcpt1,
Sprr2a, Chi3l3, Chi3l4, Chia, Pde4b, Pde4d,
Slc7a2, Tgfb1), as well as 7 cytokine genes
associated with asthma and/or pulmonary
inﬂammation (Ifnγ, Il1b, Il4, Il6, Il10, Il13,
Tnfa). The results of the four individuals in
each treatment group were averaged, as they
were with microarray analysis, to arrive at a
fold change value for the treatment group.
We converted RNA from each sample to
cDNA with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster
City, CA). We performed real-time PCR on
cDNA with a Model 7300 Real-Time PCR
System with TaqMan Universal PCR Master
Mix and TaqMan Gene Expression Assays
(Applied Biosystems) for the selected genes.
All data collected and analyzed here adhere to
the guidelines for Minimal Information About
a Microarray Experiment (MIAME 2007).
Results
An ETS trend detected in pathophysiologic
data (Penn et al. 2007) is supported in the
present study by differential gene expression in
ESO versus ASO mice. After REDI and PADE
analyses, 80 transcripts in our study met all ﬁl-
tering criteria (fold change ≥ 1.5, FDR < 0.05,
transcript p-value < 0.05). After removal of
duplicate, unmapped, and poorly characterized
transcripts, 60 unique transcripts (51 down-
and 9 up-regulated) remained that were differ-
entially expressed in the lungs of ESO versus
ASO mice (Table 1). The actual limits of ﬁlter-
ing criteria for these genes were fold change
3.25 to 1.67 and –3.37 to –1.58, FDR < 0.04,
transcript p-value < 0.005. None of the
asthma-related genes that we targeted for
analysis (Table 2) were differentially expressed
according to ﬁltered microarray data in ESO
versus ASO mice. However, when examined
by qRT-PCR, four asthma-related genes were
identiﬁed as up-regulated (Arg1, Ccl24, Slc7a2,
Mcpt1). In each case, the fold change from the
microarray analysis was very similar to that
determined by qRT-PCR (Table 2). Neither
microarray analysis nor qRT-PCR revealed dif-
ferential expression of cytokine genes in ESO
versus ASO mice (Table 3).
A significant ETS effect demonstrated
pathophysiologically (Penn et al. 2007) is sup-
ported here by differential gene expression in
EOO versus AOO mice. After REDI and
PADE analyses, 85 transcripts were initially
identiﬁed. Filtering criteria for these transcripts
were: fold change 2.13 to 1.50 and –3.24 to
–1.50, FDR ≤ 0.041, transcript p-value
< 0.005. Removal of duplicate, unmapped,
and poorly characterized transcripts left
31 down-regulated and 41 up-regulated tran-
scripts differentially expressed in EOO mice
relative to AOO controls (Table 4). Among
the down-regulated genes, one asthma-related
gene (Ccl8) met the filtering criteria. The
qRT-PCR analysis of these samples verified
results for Ccl8 and indicated a down-
regulation of 10 other asthma-related genes
(Arg1, Ccl11, Ccl24, Ear11, Mcpt1, Sprr2a,
Chi3l3, Chi3l4, Chia, Slc7a2) in EOO versus
AOO mice (Table 2). Evaluation by qRT-PCR
demonstrated down-regulation of 6 cytokine
genes in EOO mice relative to AOO mice
(Il4, Il6, Il10, Il13, Tnfa, Il1b; Table 4).
Rouse et al.
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Table 2. Differential expression of asthma-related genes: microarray versus qRT-PCR.
Sprr2a Ccl8 Ccl11 Ccl24 Ear11 Mcpt1 Arg1 Chi3l3 Chi3l4 Chia Pde4b Pde4d Slc7a2 Tgfβ1
AOO vs ASO
Array –5.6a –1.8 –3.8b –2.6a –4.6b –1.3a –6.3a –1.5d –12.6 –2.2a 1.6b 1.1d –1.3d –1.1a
PCR –17.3 –2.9 –3.6 –4.7 –5.0 –2.0 –5.8 –3.6 –18.5 –3.9 1.3 1.1 –1.6 –1.1
ESO vs ASO
Array 1.1a –1.1a 1.3a 1.8a 1.3a 1.2a 2.2a 1.1d –1.0a 1.2a –1.1d 1.1d 1.7b –1.1a
PCR –1.0 1.0 1.2 2.1 1.4 1.7 2.4 1.2 –1.1 1.2 1.1 1.0 1.7 1.2
EOO vs ESO
Array –7.3c –5.2 –7.0 –5.2a –23.8 –1.5 –22.0 –3.6e –45.7 –4.3 4.8 1.1d –1.6b –1.6a
PCR –131.4 –8.2 –7.7 –17.0 –41.3 –11.2 –26.8 –17.6 –228.5 –8.3 1.0 1.1 –4.0 –1.8
EOO vs AOO
Array –1.4d –3.2 –1.5a –1.1a –4.1a 1.0a –1.6a –2.1e –3.7a –1.6a –1.1d 1.1d –1.2d –1.3a
PCR –7.9 –2.8 –1.7 –1.8 –5.7 –3.2 –1.9 –4.1 –13.6 –1.8 –1.1 1.1 –1.5 –1.4
aDid not pass transcript p-value or FDR. bDid not pass FDR. cAverage of two transcripts for same gene; one did not pass FDR. dAverage of two transcripts; did not pass transcript p-value
or did not pass FDR. eAverage of two transcripts for same gene. All values represent fold difference (in both magnitude and direction) between the group named ﬁrst and the group
listed second.
Table 3. Differential expression of cytokine genes: mircroarray versus qRT-PCR.
Ifnγ Il1b Il4 Il6 Il10 Il13 Tnfα
AOO vs ASO
Array –1.1a –1.1a –1.2b –1.0a –1.1a –1.4b –1.1a
PCR –1.1 –1.1 –2.1 –1.6 –1.7 –4.9 –1.2
ESO vs ASO
Array –1.0a –1.4a 1.3a –1.1a –1.1a –1.3a –1.1a
PCR 1.1 –1.1 1.3 –1.3 –1.2 –1.1 1.0
EOO vs ESO
Array –1.0a –1.3a –1.7c –1.0a –1.2a –1.1a –1.2a
PCR –1.6 –1.6 –4.7 –2.2 –4.8 –17.2 –2.1
EOO vs AOO
Array –1.0a –1.6a –1.1a –1.0a –1.0a –1.0a –1.1a
PCR –1.3 –1.6 –1.8 –1.9 –3.2 –3.8 –1.8
aDid not pass transcript p-value or FDR. bAverage of two transcripts, did not pass transcript p-value or FDR. cDid not pass
FDR. All values represent fold difference (in both magnitude and direction) between the group named ﬁrst and the group
listed second.In utero ETS alters adult lung gene expression
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Table 4. Genes differentially expressed by microarray in OVA-tolerized mice exposed in utero to ETS or AIR (EOO vs. AOO).a
Fold Transcript Gene
Affymetrix ID change FDR p-Value symbol Protein family Function Process
1425206_a_at 2.13 < .001 0.0002 Ube3a Enzyme Ubiquitin conjugation Protein catabolism
1415854_at 1.94 < .001 0.0006 Kitlg Cytokine Erk, Mapk, Akt activation Proliferation signaling
1417188_s_at 1.94 < .001 0.0009 Hip2 Transcription regulator Activate transcription Ubiquitin regulation
1449217_at 1.87 0.041 0.0028 Casp8ap2 Protease activator NFκB activation Apoptosis/survival signaling
1450924_at 1.83 < .001 0.0005 Hdgfrp3 Protein binder Bind growth factor Regulation of growth factor
1422975_at 1.80 < .001 < .0001 Mme Peptidase Degrade bradykinin/elastin Extracellular matrix repair
1428025_s_at 1.80 < .001 0.0004 Pitpnc1 Transport protein Phosphatidylinositol binding Phosphatidylinositol regulation
1436917_s_at 1.76 0.041 0.0031 Gpsm1 G-protein receptor Activate GTPases Regulate G-protein receptor activity
1421230_a_at 1.74 0.041 0.0033 Msi2h Unknown Unknown Unknown
1418489_a_at 1.73 < .001 0.0001 Calcrl G-protein receptor Mobilize calcium/cAMP Control smooth muscle migration
1451866_a_at 1.73 < .001 0.0003 Hgf Cytokine Erk, Mapk activation Suppress dendritic cell activation
1453139_at 1.72 < .001 0.0002 Nudt12 Phosphatase Hydrolase Nucleotide regulation
1425845_a_at 1.68 0.041 0.0012 Shoc2 Protein binder Co-inhibitor of Raf1 Regulate Ras pathway
1447926_at 1.67 0.041 0.002 Arl5 GTPase Unknown Unknown
1417069_a_at 1.67 0.041 0.0015 Gmfb Cytokine NFκB activation Apoptosis/survival signaling
1448665_at 1.67 0.041 0.0015 Dmd Protein binder Actin binding Cytoskeletal anchoring
1451146_at 1.66 0.041 0.0016 Zfp386 Transcription regulator Chromatin/DNA binding Unknown
1449888_at 1.66 0.041 0.0016 Epas1 Transcription regulator Activate Vegf Control vascular remodeling
1418231_at 1.64 0.041 0.0011 Lims1 Adapter protein Pi3k, Akt activation Integrin signaling
1420514_at 1.64 0.041 0.0016 Tmem47 Unknown Unknown Unknown
1437784_at 1.63 < .001 0.0002 Runx1t1 Transcription regulator Increase Myc, Jun expression Proliferation/growth
1437668_at 1.63 0.041 0.0014 Ccrl1 G-protein receptor Activate T-cell/dendritic cytokines Immune signaling
1426517_at 1.61 < .001 0.0002 Gnaz Enzyme GTP/Erk, Mapk activation Differentiation signaling
1447944_at 1.61 < .001 0.0001 Zkscan1 Unknown Unknown Unknown
1425370_a_at 1.60 0.041 0.0021 Erg Transcription regulator Increase Tgfb2 expression Inhibit apoptosis
1451827_a_at 1.60 0.041 0.0011 Nox4 Enzyme NADPH oxidase ROS metabolism/inhibit proliferation
1428345_at 1.58 0.041 0.0018 Ppapdc2 Phosphatase Diphosphate phosphotase Inhibit PMN-mediated inﬂammation
1429776_a_at 1.57 0.041 0.0022 Dnajb6 Small heat shock protein Co-chaperone (hsp70) Protein transport and folding
1419805_s_at 1.57 0.041 0.0021 Ggps1 Enzyme Prenyltransferase Sterol synthesis
1437302_at 1.56 0.041 0.001 Adrb2 G-protein receptor Erk, Mapk activation Motility/adhesion signaling
1418780_at 1.55 < .001 0.0001 Cyp39a1 Enzyme Hydroxylase Lipid metabolism
1437982_x_at 1.54 0.041 0.0015 Cox15 Enzyme Cytochrome c assembly Oxidative phosphorylation
1438530_at 1.54 < .001 0.0002 Tfpi Protease inhibitor Inhibition of F10 Coagulation regulation
1416701_at 1.53 0.041 0.0016 Rnd3 Enzyme GTP-linked protein binding Inhibit smooth muscle contraction
1452328_s_at 1.53 0.041 0.0018 Pja2 Protein binding Ubiquitin conjugation Ubiquitin regulation
1418429_at 1.53 0.041 0.0013 Kif5b Kinesin Increase microtubule mobility Cell mobility
1429434_at 1.52 0.041 0.0015 Pik3ca Kinase Erk, Mapk, Akt, Rho activation Proliferation signaling
1459973_x_at 1.51 < .001 0.0001 Dpp4 Peptidase Cytokine proteolysis Inhibit T-cell activation
1453908_at 1.51 0.041 0.0011 Ptprb Phosphatase Sodium channel regulation Proliferation signaling
1452385_at 1.51 < .001 < .0001 Usp53 Enzyme Ubiquitin-speciﬁc peptidase Ubiquitin regulation
1420019_at 1.50 0.041 0.0015 Tm4sf3b Tetraspanin Integrin binding Activation/growth signaling
1448872_at –3.24 0.041 0.003 Reg3g Growth factor Unknown Epithelial cell regeneration
1419684_at –3.19 0.041 0.0042 Ccl8 Cytokine Activate WBC cytokines Immune cell activation
1418930_at –2.99 0.041 0.0037 Cxcl10 Cytokine Mast cell/monocyte chemotaxis Inﬂammatory response
1438148_at –2.81 < .001 0.0009 Gm1960c Cytokine Macrophage chemotaxis Inﬂammatory response
1448377_at –2.63 < .001 0.0007 Slpi Peptidase inhibitor Bind peptidase/inhibit NFκB Inactivate leukocyte peptidase
1449401_at –2.42 < .001 0.0009 C1qc Complement protein Complement activation Blood cell activation
1450849_at –2.26 0.041 0.0037 Hnrpu Transport protein Tranport snRNA to cytoplasm RNA processing
1419128_at –2.19 < .001 0.0008 Itgax Integrin Adhesion/signaling Immune response
1421326_at –2.17 0.041 0.0016 Csf2rb1 Transmembrane receptor Erk, Mapk, Akt activation Proliferation, differentiation, survival signaling
1440801_s_at –2.10 0.041 0.0022 Adrbk2 Kinase G-protein receptor activation Activate receptor signaling
1416871_at –2.08 0.041 0.0025 Adam8 Translation regulator Metalloendopeptidase Release of IgE low afﬁnity receptor
1419699_at –2.02 0.041 0.0012 Scgb3a1 Cytokine Akt inhibition Epithelial cell differentiation
1447071_at –1.85 0.041 0.0025 Tcf7l2 Transcription regulator Activate transcription T-cell extravasation
1437864_at –1.83 < .001 0.0001 Adipor2 Lipoprotein binder Activate Ampk Lipid metabolism
1417025_at –1.80 0.041 0.001 H2-Eb1d Transmembrane receptor MHC II antigen binding Antigen presentation
1456022_at –1.78 0.041 0.0015 Hipk2 Kinase Increase Tgfβ, Jnk transcription Cell cycle progression signaling
1425477_x_at –1.73 0.041 0.0008 H2-Ab1e Transmembrane receptor MHC II antigen binding Antigen presentation
1446050_at –1.71 < .001 0.0001 Magi1 Kinase ATP-dependent Akt activation Motility/adhesion signaling
1425294_at –1.69 0.041 0.001 Slamf8 Transmembrane receptor Unknown Immune response
1450355_a_at –1.63 0.041 0.0009 Capg Protein binding Caps actin ﬁlaments Leukocyte motility and phagocytosis
1422725_at –1.63 0.041 0.0014 Mak Kinase cATP/nucleotide binding Cell differentiation signaling
1415871_at –1.61 0.041 0.0004 Tgfbi Induced protein binder Integrin binding Motility/adhesion signaling
1419315_at –1.61 0.041 0.0006 Slamf9 Transmembrane receptor Unknown Immune response
1424758_s_at –1.59 0.041 0.0012 Serpina10 Peptidase inhibitor Inhibition of F10 Coagulation regulation
1433963_a_at –1.56 0.041 0.0006 BC032204f Enzyme Unknown Unknown
1429475_at –1.56 0.041 0.0008 Sts1 Enzyme Ubiquitin conjugation Suppress T-cell signaling/endocytosis
1419721_at –1.55 0.041 0.0005 Gpr109b G-protein receptor Inhibit cAMP Lipid metabolism
1426324_at –1.54 0.041 0.0006 H2-D1g Transmembrane receptor MHC I antigen binding Antigen presentation
1425837_a_at –1.53 0.041 0.0009 Ccrn4l Transcription regulator Activate RNA polymerase II Circadian rhythm
1416985_at –1.51 < .001 < .0001 Sirpa Phosphatase Erk, Mapk, Akt inhibition Immune signaling
1428942_at –1.50 0.041 0.0002 Mt2a Metallic ion binder NFκB activation Apoptosis/survival signaling
Gene annotations are from Affymetrix GeneChip Mouse Genome 430 2.0 Array (http://www.affymetrix.com/products/arrays/speciﬁc/mouse430_2.affx).
aMice received in utero ETS or ﬁltered AIR, were OVA-tolerized through repeated aerosol exposures and then OVA-sensitized (ip OVA injections) and challenged (OVA-aerosol) as described in
“Materials and Methods.” bTspan8. cCxcl2. dHuman homologue HLA-DRB1. eHuman homologue HLA-DQB2. fUrp2. gHuman homologue HLA-C.Again, differential expression of these cytokines
was not detected by microarray.
Gene expression comparisons of ASO ver-
sus AOO or ESO versus EOO mice reveal that
differences exist primarily as a result of airway
inﬂammation present in mice not previously
exposed to OVA (ASO and ESO) and absent
in mice previously exposed to OVA (AOO and
EOO). AOO mice had 673 down- and 1,037
up-regulated transcripts relative to ASO mice,
whereas EOO mice had 847 down- and 1,465
up-regulated transcripts relative to ESO mice
(data available upon request). In each of these
cases, unidentiﬁed, duplicate, and unmapped
transcripts accounted for 15–25% of the total
transcripts.
For ESO versus ASO and EOO versus
AOO comparisons, we organized genes into
networks and identiﬁed genes within canoni-
cal pathways based on reference literature. The
analyses allowed identiﬁcation of experimen-
tally denoted genes within deﬁned functional
pathways and networks based upon previously
identiﬁed gene–gene or protein–protein rela-
tionships. Within the ESO–ASO comparison,
34 genes (8 up-regulated and 26 down-regu-
lated) had demonstrable network connections
(Figure 2). Among the down-regulated genes
were 9 involved in promoting proliferation/
differentiation/growth (Tspan31, Pmnt, Pthlh,
Sf1, Rasgrf2, Igh-V3609N, Ankra2, Csf1, Ihh)
and 4 associated with increased ubiquitina-
tion/apoptosis (Mrcl3, Rbck1, Bmf, Lrp3).
Among the up-regulated genes were 3 associ-
ated with inhibition of proliferation (Gpnmb,
Setd8, Runx2) and 1 promoting inﬂammatory
and immune responses (Pik3cd), as well as
4 asthma-related genes (Arg1, Ccl24, Slc7a2,
Mcpt1) identiﬁable only through qRT-PCR.
Within the EOO–AOO comparison, 71
genes (43 down-regulated and 28 up-regulated)
had documented network connections
(Figure 3), including the 14 genes identiﬁed by
qRT-PCR. Of 43 down-regulated genes, 32
enhance immune and inﬂammatory responses
or have been implicated in asthma pathogene-
sis, including 6 cytokine (Il1b, Il4, Il6, Il10,
Il13, Tnfa), 4 chemokine (Ccl8, Ccl11, Ccl24,
Cxcl10), and 8 asthma-related genes (Arg1,
Ear11, Mcpt1, Sprr2a, Chi3l3, Chi3l4, Chia,
Slc7a2). Among the up-regulated genes were
6 involved in positive regulation of prolifera-
tion/differentiation/growth (Kitlg, Runxlt1,
Gnaz, Pik3ca, Ptprb, Tmrsf3), 7 associated with
increased ubiquitination/apoptosis (Ube3a,
Hip2, Casp8ap2, Gmfb, Erg, Pja2, Usp53), and
4 involved in suppression of immune responses
(Hgf, Ppapdc2, Rnd3, Dpp4). The majority of
differentially expressed genes that we discov-
ered affecting immune function are not dis-
cussed within this report but are discussed in




This is the ﬁrst report to identify gene expres-
sion changes in the adult lung following ETS
exposure in utero. In addition the gene expres-
sion results presented here (microarray and
qRT-PCR) provide a molecular framework
within which to consider the pathophysiologic,
lung function, and inﬂammatory responses we
recently reported (Penn et al. 2007).
The ETS exposure level (TSP =
10 mg/mm3) used in this study is the same
used in our other in utero (Yang et al. 2004)
and earlier adult exposure studies (Bowles et al.
2005; Penn and Snyder 1993). The associated
steady-state CO levels are approximately dou-
ble those detected in a typical indoor smoking
area (Penn et al. 1994). This exposure level,
while higher than that found in a smoking
household, is well below that used in numer-
ous published studies. In light of the indirect
(in utero) nature of these exposures and the
lack of literature on the delivered fetal dose
with varying levels of maternal ETS exposure,
we selected an exposure that we felt would be
sufﬁcient to elicit a detectable response while
not being beyond physiologic reality. 
We have carried out multiple in utero ETS
exposure experiments with 13–30 mice per
mixed-sex treatment group (Penn et al. 2007;
Rouse RL and Penn AL, unpublished observa-
tions). In these studies, there were no demon-
strable sex-related differences among offspring
in immune responses, histopathology, lung
function, or clinical pathology. These results
do not predict a significant sex difference in
gene expression. Nevertheless, only female off-
spring samples from our earlier study (Penn
et al. 2007) were used in the present gene
studies to rigorously control for subtle, unde-
tected sex influences. The gene expression
results we report here for those female off-
spring correlate well with the pathology and
lung function results from that earlier study.
Another recent in utero study demon-
strated differential DNA methylation leading
to modulated gene expression as a result of
altered maternal diet (Dolinoy et al. 2006). No
sex differences were detected within that study
as well. Sex differences have, however, been
reported for some adult responses to in utero
stresses. In an earlier collaborative study, we
demonstrated that in utero ETS exposure
(identical to that used in this experiment) pro-
duces signiﬁcant acceleration of atherosclerotic
plaque development in male apoE–/– mice
Rouse et al.
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Figure 2. Literature-described gene network, including differentially expressed genes (ESO vs. ASO mice)
from the lungs of in utero ETS-exposed mice versus in utero AIR-exposed mice that were subsequently
OVA-sensitized and OVA-challenged (ESO, ASO). Green represents down-regulation and red up-regulation
(fold-changes ≥ 1.5); white nodes represent fold-change < 1.5. Intensity of color increases with increasing
fold change (numbers represent fold change values). Dotted lines indicate indirect relationships and solid















Transporter(Yang et al. 2004). A similar trend existed
within female mice, but it did not reach a level
of statistical signiﬁcance. In contrast, there is a
report that male but not female BALB/c mice
that had been exposed in utero to mainstream
smoke from 1R3F research cigarettes [not ETS
from the lower tar, lower nicotine 1R4F ciga-
rettes (Davis et al., 1984) used here] displayed
increased tumor incidence and size associated
with decreased cytotoxic T-lymphocyte activity
after injection of EL4 lymphoma cells (Ng
et al. 2006). The variation in these reports on
sex effect illustrates the difﬁculty in predicting
adult sex-specific responses associated with
prior in utero stresses and strongly suggests that
different molecular mechanisms operate
dependent on test agent, exposure conditions,
subject strain, and experimental end points.
In ESO versus ASO mice, we identified
differentially expressed genes that participate
primarily in cell proliferation, cell motility/
elasticity, cell survival, and general cell metab-
olism (Table 1). These biological functions
are mediated at the molecular level by down-
regulation of adhesion/apoptosis signaling
molecules, transcription activating DNA-
binding motifs, adenosine triphosphate/
guanosine triphosphate (ATP/GTP) metabolic
reagents, and cytoskeletal structural compo-
nents and binding elements. Up-regulated
genes contribute to these biological processes
through negative regulation of cell proliferation,
repression of transcription, and chromatin
remodeling. Again, this is accomplished
through altered adhesion, transcription,
metabolism, and cytoskeletal elements
A single kinase gene (Pik3cd) known to
participate in immune and inﬂammatory sig-
naling through nuclear factor kappa B
(NfκB), extracellular signal-regulated kinase
(Erk), and mitogen-activated protein kinase
(Mapk) pathways was up-regulated. Nfκb,
Erk, and Mapk participate in inflammation
processes (Roux and Blenis 2004), including
those in the lung (Wuyts et al. 2003). Pik3cd
also has been linked to the increased vascular
permeability observed in inflammation (Lee
et al. 2006). Four genes linked to asthma or
lung inflammation (Arg1, Ccl24, Slc7a2,
Mcpt1) that did not pass all the microarray
ﬁltering criteria were conﬁrmed by qRT-PCR
as being up-regulated in ESO versus ASO
mice, which is consistent with an enhanced
lung response in ETS-exposed mice. Both
Arg1 and Slc7a2 have been implicated in
arginine metabolism (Zimmermann et al.
2003). Arginine serves as a substrate for both
arginase 1 and nitric oxide (NO) synthetase.
Thus, increases in arginine metabolism cat-
alyzed by arginase 1 are believed to decrease
the production of NO via NO synthetase.
Normal relaxation of smooth muscle is NO
dependent, and decreases in NO are thought
to contribute to smooth muscle–mediated
broncho-constriction, such as that seen in
asthma. Scl7a2 (CAT2) is a cationic amino
acid transporter involved in arginine transport.
Altered arginine transport affects the arginine
metabolic pathway and may also alter NO
production. Ccl24 (eotaxin 2) plays a role in
eosinophil recruitment to the lung in allergic
asthma (Panina-Bordignon and D’Ambrosio
2003). The Mpct family contains mast cell-
speciﬁc proteases that participate in mast cell
activation and degranulation (Small-Howard
and Turner 2005). Changes in cytoskeletal
elements and binding can confer relaxed cell-
to-cell attachment and facilitate inﬁltration of
inﬂammatory elements. The gene expression
proﬁle reported here indicates that adult mice
exposed in utero to ETS have increased lung
inﬂammation in response to OVA relative to
in utero air-exposed cohorts. These results sup-
port the functional, histopathologic, and
immune system changes we have documented
in OVA-sensitized and challenged mice (Penn
et al. 2007).
Figure 2 illustrates a literature-based gene
network to which our differentially regulated
gene findings (ESO vs. ASO comparison)
have been applied. This network brings
together, through our data, groups of relation-
ships that become associated for the ﬁrst time,
creating a custom network of differential gene
response for our experiment. This custom
network shows that the differences seen
between our treatment groups are based on
differential regulation of a dispersed and var-
ied group of genes in clustered relationships
with inﬂammatory/asthma genes that are not
differentially regulated. The majority of these
differentially regulated genes does not have
direct ties to the immune system or previously
deﬁned inﬂammatory responses. None of the
well-deﬁned asthma/inﬂammatory genes (Il1b,
Il4, Il10, Il13, Il6, Tnfa, Infg, Tgfb1) are dif-
ferentially expressed, although they connect
many of the genes that are. This is not surpris-
ing, as the comparison is between two groups
(ESO, ASO) that both exhibit marked
eosinophilic airway inflammation following
classic OVA sensitization/challenge. However,
the few asthma/inflammatory genes that are
differentially expressed (Pik3cd, Arg1, Slc7a2,
Ccl24, Mcpt1) are all up-regulated in ETS-
exposed mice. The mild enhancement of
inﬂammatory/immune response indicated by
these gene changes is reflected in the patho-
physiologic responses of the two groups (Penn
et al. 2007) and raises concern that ETS may
mediate increased inﬂammatory injury or alter
immune response upon initial exposure to an
infectious agent such as respiratory syncytial
virus (Phaybouth et al. 2006).
In EOO versus AOO mice, differentially
expressed genes participate in adaptive immune
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Figure 3. Literature-described gene network, including differentially expressed genes (EOO vs. AOO mice)
from the lungs of in utero ETS-exposed mice versus in utero AIR-exposed mice, that were OVA-tolerized
and then OVA-sensitized and challenged (EOO, AOO). Green represents down-regulation and red up-
regulation (fold-changes ≥ 1.5); white nodes represent fold change < 1.5. Intensity of color increases with
increasing fold change (numbers represent fold change values). Dotted lines indicate indirect relation-
ships and solid lines direct interactions. All gene symbols are human homologue designations. Network














Transporterresponses, cell proliferation, and survival, and
cell cycle control (Table 4). These processes are
controlled through down-regulated adhesion,
major histocompatibility complex (MHC),
immune, and proinflammatory molecule
genes, including cytokines and chemokines.
Up-regulated genes influence these processes
through alterations in G-protein receptor sig-
naling and cell proliferation, differentiation,
metabolism, and morphology. Consistent
down-regulation of critical inﬂammatory genes
in ETS- and doubly OVA-exposed mice was
confirmed through qRT-PCR, revealing
down-regulation of 17 asthma-related and/or
inﬂammatory genes (Arg1, Ccl8, Ccl11, Ccl24,
Ear11, Mcpt1, Sprr2a, Chi3l3, Chi3l4, Chia,
Slc7a2, Il4, Il6, Il10, Il13, Il1b, Tnfa).
Genes directly or indirectly inhibiting
immune responses were up-regulated. Genes
promoting immune responses were down-
regulated, including genes for the proinﬂam-
matory/Th2 cytokines IL-1b, IL-4, IL-6,
IL-10, IL-13, and TNF-α. Proinflammatory
cytokine genes (Il1b, Il6, Tnfa) were down-
regulated in EOO mice, decreasing innate
inﬂammatory potential, as seen in endotoxin
tolerance (Cook 1998). Down-regulation of
Th2 cytokine genes (Il4, Il10, Il13), as
described in our data, has been reported in
alloreactive T cells in which tolerance has been
induced and immune rejection suppressed
(Taylor et al. 2002). The gene for IL-10,
which is essential for the eosinophilic inﬂam-
mation seen in asthma (and in this mouse
model), is down-regulated, resulting in
decreases in mucus production and eosino-
philic inﬂammation without decreased IgE or
IL-4 (Yang et al. 2000).
Almost all differentially expressed genes
participating in the immune, inflammatory,
and asthma reactions are modulated toward
reduced responsiveness in the in utero ETS-
exposed mice (EOO vs. AOO). The effect of
this differential expression—decreased antigen-
presenting capacity and dampened immune
signaling—implies decreased innate and adap-
tive immune responses to new challenges, as
well as reduced inﬂammation. We have previ-
ously demonstrated these dampened responses
in OVA-tolerized mice that were subsequently
sensitized and challenged (Penn et al. 2007).
Figure 3 illustrates a literature-based net-
work of relationships between differentially
expressed genes that we identified in the
EOO versus AOO comparison. This network
connects, through our data, groups of previ-
ously described relationships that have not
been previously associated. The resulting cus-
tom network demonstrates that the signifi-
cant, observed, immune response differences
seen in this comparison (EOO vs. AOO) are
related to differential regulation of genes that
collectively suppress immune responsiveness.
Major inﬂammatory/immune genes (Il1b, Il4,
Il10, Il13, Il6, Tnfa) that are down-regulated
in EOO mice relative to AOO mice appear
connecting many up- and down-regulated
genes negatively regulating the immune
response. The specificity of this suppressive
modulation is of concern. Would exposure to
alternate antigens within this environment of
immune down-regulation elicit appropriate
innate and/or adaptive responses? Agents,
identiﬁed by MHC molecules or neutralized
by effector cells that are down-regulated by
in utero ETS exposure, could escape detection
or elicit suboptimal immune responses.
Although our main interest was the effect
of ETS on lung responses to OVA in both
sensitized and tolerized mice, it is noteworthy
that the number and magnitude of differences
between ESO and EOO mice greatly exceed
those between ASO and AOO mice (Tables 1
and 2). In all the asthma-related genes exam-
ined, ESO–EOO differences were consistently
greater (qRT-PCR) than ASO–AOO differ-
ences. This net effect is a result of the mild-to-
moderate increase in responsiveness of ESO
mice compared with ASO mice and the much
greater suppression of response in EOO mice
relative to AOO mice. The relative responsive-
ness or reactivity of these four groups of mice,
indicated by their general gene expression pro-
files as well as by their relative expression of
specific asthma/inflammatory genes, is sup-
ported by histopathology, BAL cell counts and
cytokine analyses, immunoglobulin levels, and
AHR (Penn et al. 2007). In each comparison,
additional candidate genes (white nodes in
Figures 2 and 3) warrant future investigation.
In our comparison of gene expression
between ESO mice and ASO mice, it was evi-
dent that genes for cell proliferation, growth,
and general metabolic processes were more
suppressed in the most reactive group (ESO).
Inﬂammation is associated with proliferation
of innate and adaptive immune cells. However,
activation of the p38 pathway (Diehl et al.
2000) and Pik3cd (Donahue and Fruman
2004) can result in cell cycle arrest and halt cell
proliferation and growth in lymphocytes.
Findings in the EOO versus AOO mice indi-
rectly support the ﬁndings in ESO versus ASO
mice. The least-responsive group (EOO) had a
differential expression proﬁle that was indica-
tive of increased cell proliferation, growth, and
metabolism. Because our lung samples repre-
sent total lung RNA, proliferation status of
nonimmune cells is also reﬂected in the differ-
ential expression. Fibroblasts have been impli-
cated in maintenance of the local environment
(extracellular matrix) within tissues, including
down-regulation of inflammatory responses
(Buckley et al. 2001). Proliferation of regula-
tory fibroblasts might overshadow down-
regulation of proliferation in immune cells.
The fate of T cells, activation or anergy,
has been tied to both cell cycle progression
(Wells et al. 2000) and intracellular calcium
ﬂux (Gavin et al. 2002). Evidence for regula-
tion of both the cell cycle and of ion channels
is presented in our data (Tables 1 and 4). The
ultimate fate of the immune response will
depend on the character of the T cells involved
(T-effector vs. T-regulatory) as well as on the
presence of co-stimulators, MHC expression,
and innate immune elements. An attenuation
of innate and adaptive responses, if nonspeciﬁc,
might threaten the ability of the least-responsive
group (EOO) to respond appropriately to an
infectious agent. Similarly, excessive airway
inflammation might impair defenses or
increase injury during infection (Beisswenger
et al. 2006) in the most-responsive group
(ESO). Thus, either extreme of the ETS-based
responsive dichotomy may be undesirable
(Clark and Kupper 2005).
Our data comparing two aerosol-tolerized
groups (EOO, AOO) illuminate the complex-
ity of immune tolerance. The dynamic nature
of tolerance, involving the down-regulation and
inhibition of numerous biological processes that
collectively potentiate the immune system, is
well illustrated by our data. Although anergy of
speciﬁc T-cell lines plays a signiﬁcant role in
tolerance, many other “players” (dendritic cells,
PMN’s, mast cells, macrophages, eosinophils)
are suppressed via multiple mechanisms,
including structural and enzymatic changes
yielding functional impairments. In vivo, toler-
ance is the sum of suppressed stimulation/acti-
vation (decreased antigen presentation, T-cell
anergy, dampened intracellular signaling) and
impaired effector function (depressed chemo-
taxis, protease inhibition, suppressed cell mobil-
ity). Our data define multiple sites and
diversities in mechanisms involved in inhibiting
the immune system and achieving tolerance.
In the present study we also demonstrate
that varying degrees of responsiveness can exist
within the tolerant population. Although both
EOO and AOO mice demonstrated no IgE or
eosinophilic inflammation (and thus were
considered tolerant), the AOO group had
higher levels of Th2 cytokines, BAL inflam-
matory cells, airway hyperresponsiveness, and
airway pathology (Penn et al. 2007). In all
cases, AOO mice demonstrated more response
in pathology, cytokine production, immune
cell accumulation in the airway, and airway
hyperreactivity, and in many of these cases the
differences were signiﬁcant. Differential gene
expression data reveal more gene alterations
inhibiting the immune response in EOO ver-
sus AOO mice. These differences, initiated by
an environmental exposure limited to the ges-
tational period, may not be totally antigen
speciﬁc and therefore are potentially detrimen-
tal. Certainly, the difference between respon-
siveness in EOO and AOO mice is a reﬂection
of the mechanisms involved in tolerance
induction.
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Alteration of gene expression mediated by
in utero environmental exposure represents a
change in phenotype determined by gene-envi-
ronment interaction. The mechanism by
which these gene expression changes are
orchestrated is not yet deﬁned, but epigenetic
involvement is likely (Drake et al. 2005;
Rahnama et al. 2006; Waterland and Jirtle
2003). Given the number and variety of genes
that we found to be differentially regulated,
along with the indirect and relatively mild
nature of exposures that culminated in demon-
strable response differences in immunology,
histopathology, clinical pathology, and lung
function, the search for single candidate genes
may need to evolve to an examination of
global epigenetic alterations. In most cases,
gene–environment interactions may cause
transient, reversible, or noncritical alterations
in gene expression, or no detectable change in
phenotype. However, the ability of relatively
mild in utero environmental exposures during
embryonic development to modulate adult
gene expression may move chronic adult dis-
eases (atherosclerosis, obesity, diabetes,
allergy, asthma) into the realm of early devel-
opmental disorders such as childhood dia-
betes, leukemia, and autism that also appear
to be environmentally modulated.
Genes recognized in this study are present
in other tissues and may have varied and
diverse functions beyond those described here.
However, the functions delineated within this
present study are consistent with the patho-
logic and physiologic differences defined by
the study exposures. Gene ontogeny has been
examined in context of the complexity of an
in vivo system. Further reﬁnement of speciﬁc
cell types involved and speciﬁc mechanisms of
differential gene regulation are ongoing, par-
ticularly gene-specific and global changes in
epigenetic modiﬁcations.
Conclusion
In utero ETS exposure alters gene expression in
the lung of adult BALB/c mice in response to
OVA exposure, regardless of whether that expo-
sure was sensitizing or tolerizing. The results
support a gene–environment interaction that
results from in utero ETS exposure and that
alters the phenotype of adult mice as deﬁned by
their gene expression and inflammatory
responses to an allergen (OVA). The strength
of these ﬁndings is re-enforced by the consis-
tency of relative group responses across gene
expression data, airway function (reactivity)
changes, presence of airway inflammatory
mediators (cytokines, cells), and lung histo-
pathology. Our data implicate milder, wide-
spread gene expression changes rather than (or
in addition to) larger more discrete alterations
in single gene expression as the mechanism
through which these in utero exposures alter
adult lung responses.
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